Navigation Links
New recommendations issued for use of cetuximab in colon cancer therapy
Date:7/16/2010

Chapel Hill, NC In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

Based on earlier studies, cetuximab is now indicated for treatment of patients with advanced colorectal cancer whose tumors do not have a mutation in the KRAS gene. KRAS is one of a series of genes along a pathway that can lead tumors cells to grow, divide and evade signals that shut the cells down causing their death. Based on the results in advanced disease, researchers had hoped to see similar benefits when cetuximab was added to a standard chemotherapy regimen in earlier stages of colon cancer. However, ongoing analysis during the clinical trial found that patients receiving the combination therapy had no significant improvement in survival compared to standard therapy.

Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) a cell signaling pathway that contributes to tumor growth. The drug is given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer. Previously, researchers found that patients with a mutated KRAS gene about 40 percent of those with metastatic colon cancer do not respond to the EGFR inhibitors currently in use.

However, the genetic test for KRAS mutation was not standard until this trial was well underway. Patients enrolled before KRAS testing were segmented from those in the rest of the study and analyzed separately, said Richard Goldberg, MD, chief of the division of hematology/oncology at the UNC-Chapel Hill School of Medicine, who presented the results for this group of patients.

"We expected that patients with the genetic mutation would not respond to cetuximab, and that is what we found," said Goldberg, who is also physician-in-chief of the N.C. Cancer Hospital.

"However, even the patients in the study whose tumors did not harbor the KRAS mutation did not benefit significantly from the combination therapy and the standard treatment proved to have the best results. We also found that the combination therapy was more toxic and the side effects of treatment especially in older patients negatively impacted their ability to complete the standard treatment," he added.

The researchers issued a recommendation that cetuximab should not be used in patients with stage III colon cancer. It remains a valuable tool in treating patients with advanced colorectal cancers whose tumors do not harbor a KRAS mutation and can either be administered as a single agent or with chemotherapy.


'/>"/>

Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. AGA offers new recommendations for CRC surveillance for certain patients with IBD
2. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
3. Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism
4. Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism
5. Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism
6. SIUE Pain Summit Recommendations Announced Today
7. G8 to receive recommendations on women and childrens health
8. ACR task force makes recommendations for improving relationships between radiologists and hospitals
9. Aspirin recommendations changed for many younger diabetic patients
10. Study finds poor compliance with cirrhosis surveillance recommendations
11. New Guidelines Issued on Hormone Receptor Testing for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
(Date:1/19/2017)... ... , ... This month, the CEO and Clinical Director of Sober Living Outpatient, ... in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO Recovery ... Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed kids ...
(Date:1/19/2017)... ... 19, 2017 , ... Remote Medical Technologies (RMT), the leader ... with their iMedHD2™ Portable Teleultrasound System. Compatible with any ultrasound ... HD, dynamic, streaming ultrasound images and video to one or more distant locations ...
(Date:1/19/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it will be co-hosting a workshop entitled “Develop Better ... delivery solutions to health industries worldwide. The one day event is to be ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, ... The global anti-obesity drugs market is expected to grow ... forecast period and CAGR of 38.7% in the second half of ... CAGR of 32.8% from 2016 to 2027. The market is estimated ... million in 2027. ...
Breaking Medicine Technology: